Duarte Ira has filed 39 insider transactions across 2 companies since June 2023.
Most recent transaction: a grant/award of 216562 shares of HERON THERAPEUTICS, INC. /DE/ ($HRTX) on January 30, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan. 30, 2026 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | A | Restricted Stock Units | 216562 | $0.00 | 216,562.0000 | 183,362,522 | 9999.99% | 0.12% |
| Jan. 30, 2026 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | A | Performance Stock Units | 216561 | $0.00 | 216,561.0000 | 183,362,522 | 9999.99% | 0.12% |
| Jan. 31, 2026 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 11695 | $0.00 | 195,356.0000 | 183,362,522 | 6.37% | 0.01% |
| Jan. 31, 2026 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 11695 | $0.00 | 140,332.0000 | 183,362,522 | 7.69% | 0.01% |
| Jan. 19, 2026 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 3875 | $0.00 | 183,661.0000 | 183,362,522 | 2.16% | 0.00% |
| Jan. 19, 2026 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 3875 | $0.00 | 30,994.0000 | 183,362,522 | 11.11% | 0.00% |
| Oct. 31, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 11694 | $0.00 | 179,786.0000 | 183,362,522 | 6.96% | 0.01% |
| Oct. 31, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 11694 | $0.00 | 152,027.0000 | 183,362,522 | 7.14% | 0.01% |
| Oct. 19, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 3874 | $0.00 | 168,092.0000 | 152,329,588 | 2.36% | 0.00% |
| Oct. 19, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 3874 | $0.00 | 34,869.0000 | 152,329,588 | 10.00% | 0.00% |
| July 31, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 11695 | $0.00 | 163,721.0000 | 152,329,588 | 6.67% | 0.01% |
| July 31, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 11695 | $0.00 | 164,218.0000 | 152,329,588 | 7.67% | 0.01% |
| July 19, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 3874 | $0.00 | 152,523.0000 | 152,329,588 | 2.61% | 0.00% |
| July 19, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 3874 | $0.00 | 38,743.0000 | 152,329,588 | 9.09% | 0.00% |
| June 24, 2025 | TerrAscend Corp. | $TSNDF | Duarte Ira | Not found | A | Common Shares | 433653 | $0.00 | 657,930.0000 | 293,232,131 | 193.36% | 0.15% |
| June 16, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 12500 | $0.00 | 148,649.0000 | 152,329,588 | 9.18% | 0.01% |
| June 16, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 12500 | $0.00 | 25,000.0000 | 152,329,588 | 100.00% | 0.01% |
| April 30, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 11694 | $0.00 | 136,149.0000 | 152,329,588 | 9.40% | 0.01% |
| April 30, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 11694 | $0.00 | 175,416.0000 | 152,329,588 | 7.14% | 0.01% |
| April 19, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 3875 | $0.00 | 42,617.0000 | 152,329,588 | 10.00% | 0.00% |
| April 19, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 3875 | $0.00 | 124,455.0000 | 152,329,588 | 3.21% | 0.00% |
| Jan. 31, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | A | Restricted Stock Units | 187110 | $0.00 | 187,110.0000 | 0 | 9999.99% | 0.00% |
| Jan. 31, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 374220 | $0.00 | 374,220.0000 | 0 | 9999.99% | 0.00% |
| Jan. 19, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 3874 | $0.00 | 120,580.0000 | 0 | 3.32% | 0.00% |
| Jan. 19, 2025 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 3874 | $0.00 | 46,492.0000 | 0 | 7.69% | 0.00% |
| Dec. 31, 2024 | TerrAscend Corp. | $TSNDF | Duarte Ira | Not found | F | Common Shares | 71704 | $0.65 | 224,277.0000 | 288,327,497 | 24.23% | 0.02% |
| Oct. 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 3874 | $0.00 | 50,366.0000 | 0 | 7.14% | 0.00% |
| Oct. 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 3874 | $0.00 | 108,001.0000 | 0 | 3.72% | 0.00% |
| July 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 3875 | $0.00 | 104,127.0000 | 0 | 3.87% | 0.00% |
| July 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 3875 | $0.00 | 54,240.0000 | 0 | 6.67% | 0.00% |
| June 17, 2024 | TerrAscend Corp. | $TSNDF | Duarte Ira | Not found | A | Common Shares | 163334 | $0.00 | 295,981.0000 | 288,327,497 | 123.13% | 0.06% |
| June 16, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 12500 | $0.00 | 37,500.0000 | 0 | 25.00% | 0.00% |
| June 16, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 12500 | $0.00 | 100,252.0000 | 0 | 14.24% | 0.00% |
| April 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Common Stock | 3874 | $0.00 | 88,874.0000 | 0 | 4.56% | 0.00% |
| April 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | M | Restricted Stock Units | 3874 | $0.00 | 58,115.0000 | 0 | 6.25% | 0.00% |
| April 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | F | Common Stock | 1122 | $2.64 | 87,752.0000 | 0 | 1.26% | 0.00% |
| Jan. 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 371935 | $0.00 | 371,935.0000 | 0 | 9999.99% | 0.00% |
| Jan. 19, 2024 | HERON THERAPEUTICS, INC. /DE/ | $HRTX | Duarte Ira | EVP, Chief Financial Officer | A | Restricted Stock Units | 61989 | $0.00 | 61,989.0000 | 0 | 9999.99% | 0.00% |
| June 22, 2023 | TerrAscend Corp. | $TSNDF | Duarte Ira | Director | A | Common Stock | 132647 | $0.00 | 132,647.0000 | 0 | 9999.99% | 0.00% |